Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch for the Treatment of Chronic Postsurgical or Post-traumatic Neuropathic Pain: a Randomized Placebo Controlled Study in Children Aged 12 to 17-y

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Device, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study concerns children aged to 12 to 17-years with local chronic neuropathic pain after trauma or surgery. It is a multicentric randomized controlled superiority trial in parallel arms : * experimental arm: Capsaicin 8% cutaneous patch * controlled arm : Hydrocolloid dressing Treatment with capsaicin application is realized at baseline, and repeated 3 months after the first patch application if needed. Tolerance is assessed during each application and by phone call in following days until stop of cold need. Efficacy is assessed monthly by clinical consultation until the end of the study (month 4).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 17
Healthy Volunteers: f
View:

• Children aged 12 to 17 years (lower age limit of 12 has been chosen to ensure NPSI full filling).

• Male or female.

• Persistent neuropathic pain more than 3 months after surgery or trauma despite treatment following recommendations.

• Neuropathic pain is defined as a DN4 score equal to or greater than 3/7 or 4/10, and localized in a nerve territory explained by the surgery or the trauma.

• Treatment, survey and follow up must be realized in an identified investigating center of the study

• For patients of childbearing potential: use of an adequate method of contraception\* during the course of the study through 48 hours after the last patch application (girls of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the first patch application).

⁃ Adequate contraception includes sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide, combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)

Locations
Other Locations
France
CHU d'Amiens
RECRUITING
Amiens
CHU d'Angers
RECRUITING
Angers
CHU de Bordeaux
RECRUITING
Bordeaux
CHU de Brest
RECRUITING
Brest
CHU de Nantes
RECRUITING
Brest
CHU de Lyon
RECRUITING
Lyon
CHU de Marseille
RECRUITING
Marseille
CHU de Montpellier
RECRUITING
Montpellier
CHU de Tours
RECRUITING
Tours
Institut Gustave Roussy
RECRUITING
Villejuif
Contact Information
Primary
Philippe J LE MOINE, MD
philippe.lemoine@chu-brest.fr
+33298223956
Time Frame
Start Date: 2024-03-05
Estimated Completion Date: 2026-04-05
Participants
Target number of participants: 46
Treatments
Active_comparator: QUTENZA
The experimental product is QUTENZA®, a cutaneous patch which contains 179 mg of capsaicin (capsaicin 8%).The patch measures 14 cm x 20 cm.~The second application takes place three months after the first application.
Placebo_comparator: Placebo
The placebo comparator is a hydrocolloid dressing: COMFEEL PLUS TRANSPARENT, a medical device class IIb commercialized by Coloplast. The patch measures 15 cm x 15 cm.~The second application takes place three months after the first application.
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Brest

This content was sourced from clinicaltrials.gov